十一月 2025
- Home
- Concord Biotech
十一月 2025的Concord Biotech市场份额分析
Concord Biotech Limited is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation based biopharmaceutical active pharmaceutical ingredients sold worldwide.
Concord was founded in 2000 by Sudhir Vaid.
Concord Biotech(包含公司地区分支机构)
查看更多网站流量和参与度信息- concordbiotech.com
Concord Biotech收入截至 十一月 2025为 > 1B
Concord Biotech主要域名产生的收入
3 年中Concord Biotech主要域名的收入
Concord Biotech主要域名的收入
Concord Biotech热门域名的总访问量
了解Concord Biotech市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Concord Biotech热门域名的平均访问时长
分析Concord Biotech参与度指标。
过去 3 个月的平均访问时长
子公司明细
Concord Biotech热门域名的平均页面浏览量
了解Concord Biotech如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Concord Biotech 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Concord Biotech Limited had issues with marketing approval for its teriflunomide 7 mg and 14 mg tablets on Apr 8th '25.Concord Biotech on Tuesday, April 8, announced that it received marketing approval for its teriflunomide 7 mg and 14 mg tablets from the United States Food and Drug Administration (USFDA).
四月 8, 2025阅读更多
新闻Concord Biotech Limited invested into Palvella Therapeutics, Inc $1M on Dec 12th '24.Concord Biotech Ltd on Thursday said it has invested USD 10 lakh (nearly Rs 85 crore) in US-based Palvella Therapeutics, Inc with an aim to establish a partnership to manufacture and commercialise 'Qtorin', a drug used to treat serious and rare genetic skin diseases.
十二月 12, 2024阅读更多
新闻Concord Biotech Limited went public on Aug 18th '23.Concord Biotech's IPO was backed by the Jhunjhunwala family when the shares debuted in August 2023.
五月 27, 2024阅读更多
查看 Concord Biotech 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。